Description

SK-MEL-3 is one of a series of melanoma cell lines established from patient-derived tumor samples. This cell line is known to form tumors in immunocompromised mice.

Source

This cell line was established in 1972 from a metastatic site (lymph node) in a 42-year-old Caucasian female with malignant melanoma.

Inventors

• Lloyd J. Old, MD, former William E. Snee Chair in Cancer Immunology, Memorial Sloan Kettering; former Director, New York Branch, Ludwig Institute for Cancer Research
• Germain Trempe, formerly at Sloan Kettering Institute, Memorial Sloan Kettering

Key References

Fogh J et al. (1977) One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. Journal of the National Cancer Institute 59: 221-226 (PubMed ID: 327080)

Licensing Information

This cell line may be licensed nonexclusively for research or commercial purposes.

• Express License:  For internal research purposes by a for-profit entity:  1) Fill out MSK’s ATCC Express License, see here for links to the online fillable ATCC Express License, as well as a PDF version.  2) After execution by MSK, you will receive a signed copy, and can then place your order with ATCC. For detailed guidance on how to fill out this webform, see here. Please note:  In order to streamline and expedite the licensing of select MSK cell lines, the terms of this non-exclusive license are non-negotiable. This license is only available for select cell lines, including this one. Once this license has been executed by MSK, you will receive a signed copy and payment instructions; all payments up to $10,000 must be made by credit card.
• Commercial License: Contact MSK’s Tangible Materials team at [email protected].

For non-licensing requests from academic-research institutions: Contact Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354, [email protected].